- Home
- BZUN vs VTYX Comparison
BZUN vs VTYX Comparison
Compare BZUN & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZUN
- VTYX
- Stock Information
- Founded
- BZUN 2007
- VTYX 2018
- Country
- BZUN China
- VTYX United States
- Employees
- BZUN N/A
- VTYX N/A
- Industry
- BZUN Catalog/Specialty Distribution
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- BZUN Consumer Discretionary
- VTYX Health Care
- Exchange
- BZUN Nasdaq
- VTYX Nasdaq
- Market Cap
- BZUN 188.7M
- VTYX 154.9M
- IPO Year
- BZUN N/A
- VTYX 2021
- Fundamental
- Price
- BZUN $3.73
- VTYX $1.61
- Analyst Decision
- BZUN Buy
- VTYX Buy
- Analyst Count
- BZUN 2
- VTYX 4
- Target Price
- BZUN $3.20
- VTYX $11.33
- AVG Volume (30 Days)
- BZUN 532.4K
- VTYX 1.3M
- Earning Date
- BZUN 03-20-2025
- VTYX 03-04-2025
- Dividend Yield
- BZUN N/A
- VTYX N/A
- EPS Growth
- BZUN N/A
- VTYX N/A
- EPS
- BZUN N/A
- VTYX N/A
- Revenue
- BZUN $1,312,737,613.00
- VTYX N/A
- Revenue This Year
- BZUN $8.16
- VTYX N/A
- Revenue Next Year
- BZUN $4.71
- VTYX N/A
- P/E Ratio
- BZUN N/A
- VTYX N/A
- Revenue Growth
- BZUN 7.26
- VTYX N/A
- 52 Week Low
- BZUN $2.11
- VTYX $1.57
- 52 Week High
- BZUN $4.38
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- BZUN 63.06
- VTYX 34.49
- Support Level
- BZUN $3.51
- VTYX $1.57
- Resistance Level
- BZUN $3.97
- VTYX $1.78
- Average True Range (ATR)
- BZUN 0.21
- VTYX 0.10
- MACD
- BZUN 0.02
- VTYX -0.00
- Stochastic Oscillator
- BZUN 73.91
- VTYX 10.26
About BZUN Baozun Inc.
Baozun Inc is an e-commerce service partner that helps brands execute their e-commerce strategies in China by selling their goods directly to customers online or by providing services to assist with their e-commerce operations. Its integrated end-to-end e-commerce service capabilities, omni-channel expertise, and technology-driven solutions. Company have two operating segments namely E-Commerce (including BEC and BZI) and Brand Management (BBM).
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.